Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221
May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2266535/sarepta-therapeutics-srpt-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266535
May 01, 2024 - Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/05/01/sarepta-therapeutics-srpt-q1-2024-earnings-call-tr/?source=iedfolrf0000001
May 01, 2024 - SRPT earnings call for the period ending March 31, 2024.
0
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2266374/sarepta-therapeutics-srpt-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2266374
May 01, 2024 - Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2265282/biontech-bntx-to-report-q1-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2265282
Apr 30, 2024 - On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
0
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391
Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
0
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
https://www.zacks.com/stock/news/2264268/what-s-in-store-for-adma-biologics-adma-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264268
Apr 29, 2024 - On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
0
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
https://www.zacks.com/stock/news/2263473/what-s-in-store-for-puma-biotechnology-pbyi-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263473
Apr 26, 2024 - On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
0
GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001
Mar 13, 2024 - The threat is still emerging, but it could be significant.
0
Page 1>